Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-03-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司医疗器械注册申请获得优先审批的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1027 characters) from Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary receiving priority approval for a medical device registration application. It includes details about the product, regulatory body (National Medical Products Administration), and the impact and risks related to the approval process. The document does not contain financial statements or detailed financial data, nor does it present a full report. It is an official announcement about a regulatory approval status update. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit other specific categories.
2019-03-15 Chinese
关于持股5%以上股东减持股份比例达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the methods of reduction, dates, and compliance with relevant securities laws and regulations. The document does not contain financial statements or performance data but focuses on shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds.
2019-03-12 Chinese
关于2019年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the expected daily related party transactions for the year 2019. It includes extensive financial data, transaction categories, amounts, and descriptions of related parties and their relationships. The document also discusses the approval process by the board and shareholders, pricing policies, and the necessity of these transactions. It is not a full annual or quarterly financial report but a regulatory disclosure about related party transactions, which is a common regulatory filing in Chinese stock exchanges. The document is lengthy (15,000 characters) and contains substantive financial and operational details about related party transactions, not just an announcement of a report or a brief summary. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure about related party transactions required by stock exchange rules, and does not fit the definitions of Annual Report, Interim Report, or other specific categories.
2019-03-08 Chinese
独立董事关于第二届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of a board meeting agenda item related to anticipated related-party transactions for the year 2019. It references compliance with regulatory guidelines and company bylaws, and it is a statement of board/management governance activity rather than a financial report or announcement. The content focuses on board-level approval and governance procedures, fitting the category of Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of voting results. Therefore, the best classification is MANG with high confidence.
2019-03-08 Chinese
中信证券股份有限公司关于公司2019年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2019 anticipated daily related-party transactions of Shenzhen BGI Genomics Co., Ltd. It includes extensive financial data, transaction categories, pricing policies, and descriptions of related parties and their financials. The content focuses on the company's related-party transactions, their approval processes, and financial impact, which is typical of an audit or compliance report related to internal controls and regulatory requirements. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not merely an announcement or summary. It does not represent a full annual report, earnings release, or management discussion but is a specialized report on related-party transactions and their verification, which aligns with an Audit Report / Information filing type. FY 2019
2019-03-08 Chinese
独立董事关于第二届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent opinion from independent directors regarding matters discussed at the company's second board of directors' seventh meeting. It discusses opinions on related party transactions for 2019 and guarantees provided to a wholly-owned subsidiary. The content focuses on governance and compliance with regulations, board decision-making, and approval of specific corporate actions. There is no financial data, earnings information, or report publication mentioned. The document is clearly related to board/management information, specifically independent directors' opinions on board meeting matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed reports, so it is not an annual or interim report or regulatory filing. Confidence is high due to clear governance and board meeting context.
2019-03-08 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.